EthanMarko2: added first info v1 - done

2026-04-14T18:27:17Z

added first info v1 - done

New page

{{Short description|Indian pharmaceutical company}}
{{Use dmy dates|date=May 2018}}
{{Use Indian English|date=May 2018}}

{{Infobox company
| name = Granules India Ltd.
| logo = Granules_India_logo_2026.png
| logo_size = 176
| image = Granules largest single-site.jpg
| image_caption = Granules Finished Dosage unit in [[Gagillapur]]
| type = [[Public company|Public]]
| traded_as = {{BSE|532482}} {{NSE|GRANULES}}
| industry = [[Pharmaceutical company|Pharmaceuticals]]
| foundation = 1984
| founder = Krishna Prasad Chigurupati
| location = [[Hyderabad]], [[Telangana]], India
| area_served = Worldwide
| key_people = Krishna Prasad Chigurupati ([[Chairman|CMD]]) Uma Devi Chigurupati ([[Executive Director|ED]]) Priyanka Chigurupati ([[Executive Director|ED]]) Harsha Chigurupati ([[Executive Director|ED]])
| products = Finished Dosages Pharmaceutical Formulation Intermediates [[Active Pharmaceutical Ingredients]] Peptides/CDMO
| revenue = {{down}} {{INRconvert|4481.6|c}} (FY 2024-25)<ref name="fy25"/>
| operating_income = {{down}} {{INRconvert|856|c}} (FY24)<ref name="fy24">{{cite web |title=Earnings Presentation - Q4 & Full Year FY24 |url=https://www.bseindia.com/xml-data/corpfiling/AttachHis/2b4f9d1d-b4e2-4bfd-8f6d-32d5923e670f.pdf |website=BSE |publisher=Granules India Limited |access-date=10 July 2024}}</ref>
| profit = {{down}} {{INRconvert|501.5|c}} (FY 2024-25)<ref name="fy25">{{cite web |title=Granules India posts Q4 FY25 PAT at Rs. 152 Cr |url=https://www.indianpharmapost.com/news/lite/granules-india-posts-q4-fy25-pat-at-rs-152-cr-17212 |website=Indian Pharma Post |access-date=28 May 2025}}</ref>
| num_employees = 6,166 (March 2025)
| subsid = {{ubl|Granules Pharmaceuticals Inc.| Granules Life Sciences Private Limited| Granules CZRO Private Limited| Ascelis Peptides Private Limited }}.<ref> {{cite news
|title=Granules India gets USFDA tentative nod for generic ADHD treatment tablets
|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/granules-india-gets-usfda-tentative-nod-for-generic-adhd-treatment-tablets/articleshow/126410383.cms|work=The Economic Times|agency=Press Trust of India|date=2024|access-date=27 March 2026}}</ref>
| homepage = {{URL|https://granulesindia.com}}
}}
'''Granules India Limited''' is an Indian pharmaceutical manufacturing company headquartered in [[Hyderabad]], [[Telangana]], India. The company is involved in the manufacture and sale of [[Tablet (pharmacy)|finished dosage]] forms (FDs), [[pharmaceutical formulation]] intermediates (PFIs), [[Active ingredient|active pharmaceutical ingredients]] (APIs).<ref>{{Cite web|url=http://www.moneycontrol.com/news/business/granules-india-signs-dealmatchland-pty-ltd_270194.html|title=Granules India signs deal with Matchland Pty Ltd}}</ref><ref>{{cite news|url=http://www.thehindubusinessline.com/2007/05/10/stories/2007051001371700.htm|title=Granules India| date=10 May 2007|work=Moneycontrol.com|accessdate=10 December 2009}}</ref>

Granules manufactures off-patent pharmaceutical products at large scale for customers in regulated and other international markets.<ref name=":1">{{Cite news |last=Amirapu |first=Deepika |date=2011-08-26 |title=Granules India to augment APIs production, expand market share of best sellers |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/granules-india-to-augment-apis-production-expand-market-share-of-best-sellers/articleshow/9745760.cms? |access-date=2026-02-20 |work=The Economic Times |issn=0013-0389}}</ref>

The company is among the larger global manufacturers of first-line therapeutic products, including [[paracetamol]], [[metformin]], ibuprofen, [[guaifenesin]], and [[methocarbamol]].

The company manufactures pharmaceutical products across multiple therapeutic categories, including antihistamines, anti-gout agents, anti-thrombocytopenic agents, [[Diabetes medication|anti-diabetic]] drugs, [[central nervous system]] (CNS) treatments, oncology products, and mineral supplements. In 2025 company also entered the [[Peptide|peptides]] segment through the establishment of its subsidiary, Ascelis Peptides Private Limited.

==History==
Granules India was founded in 1984 as Triton Laboratories Private Limited by Krishna Prasad Chigurupati and Uma Chigurupati in Hyderabad, India.<ref>{{Cite news |last=Hindu |first=The |date=2025-06-20 |title=Granules unit in Hyderabad, one of the largest globally for paracetamol API, under U.S. FDA scanner |url=https://www.thehindu.com/business/granules-unit-in-hyderabad-one-of-the-largest-globally-for-paracetamol-api-under-us-fda-scanner/article69718076.ece |access-date=2026-01-29 |work=The Hindu |language=en-IN |issn=0971-751X}}</ref> The company initially focused on the manufacture of paracetamol active pharmaceutical ingredients (APIs) at its Bonthapally facility, located on the outskirts of Hyderabad.<ref name=":2">{{Cite web |last=Pilla |first=Viswanath |date=August 27, 2020 |title=How Granules India transformed itself from a company making commodity APIs into one making formulations |url=https://www.moneycontrol.com/news/business/companies/how-granules-transformed-itself-from-a-company-of-commodity-apis-to-formulations-with-us-focus-5762971.html}}</ref>

In 1987, Triton became the second Indian pharmaceutical company to export products to the United States,<ref name=":2" /> marking an early milestone in its international expansion.

'''1990-2000'''

During the 1990s, the company expanded its manufacturing capabilities.

In 1990, it established a second production facility in Jeedimetla to manufacture multiple APIs.<ref name=":0">{{Cite web | url=https://granulesindia.com/wp-content/uploads/pdf/Granules-AR-2022-23.pdf | title=Transforming Healthcare through Innovation and Sustainability | website=granulesindia.com}}</ref> As part of its differentiation strategy, Triton pioneered the production and sale of bulk granulated paracetamol, commonly referred to as direct compressible (DC) grade material or pharmaceutical formulation intermediates (PFIs).

In 1991, Granules India Private Limited was formally incorporated as a merchant exporter of bulk drugs.<ref name=":0" />

In 1993, the company established its first pharmaceutical formulation intermediates (PFI) facility at Jeedimetla, applying the PFI concept to multiple active pharmaceutical ingredients (APIs),<ref>{{Cite news |last=Amirapu |first=Deepika |date=2011-08-26 |title=Granules India to augment APIs production, expand market share of best sellers |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/granules-india-to-augment-apis-production-expand-market-share-of-best-sellers/articleshow/9745760.cms?from=mdr |access-date=2026-01-29 |work=The Economic Times |issn=0013-0389}}</ref> and began exporting to international markets including the United States, Germany, and [[Australia]]. <ref>{{Cite news |date=2012-07-09 |title=Granules India expansion to make it among largest single-site PFI |url=https://timesofindia.indiatimes.com/city/hyderabad/granules-india-expansion-to-make-it-among-largest-single-site-pfi/articleshow/14782551.cms |access-date=2026-01-29 |work=The Times of India |issn=0971-8257}}</ref>

Granules became a public company in 1993 and was listed following its initial public offering on the Hyderabad Stock Exchange in 1995.<ref>{{Cite web |title=Granules |url=https://www.ifc.org/en/insights-reports/2021/granules-cases-study |access-date=2026-01-29 |website=IFC |language=English}}</ref>

'''2000 -2010'''

In 2001, Triton Laboratories merged with Granules India, consolidating operations under a single corporate entity.<ref name=":0" />

In 2003, Granules commissioned what it described as the world’s largest single-site PFI manufacturing facility at [[Gagillapur]].<ref>{{Cite news |date=2007-05-14 |title=Granules India gets USFDA approval for two facilities |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/granules-india-gets-usfda-approval-for-two-facilities/articleshow/2044288.cms?from=mdr |access-date=2026-01-29 |work=The Economic Times |issn=0013-0389}}</ref> In the same year, the company established Granules US, a wholly owned subsidiary, to support marketing and distribution activities in the United States.<ref>{{Cite news |date=2025-12-22 |title=Granules unit gets USFDA nod for generic drug |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/granules-unit-gets-usfda-nod-for-generic-drug/articleshow/126116751.cms?from=mdr |access-date=2026-01-29 |work=The Economic Times |issn=0013-0389}}</ref><ref name=":0" />

In 2002, Granules India was listed on the [[Bombay Stock Exchange]] (BSE), followed by a listing on the [[National Stock Exchange of India|National Stock Exchange]] (NSE) in 2005. During this period, the company commissioned a new paracetamol manufacturing plant at [[Bonthapally]], expanding its active pharmaceutical ingredient (API) production capacity.

'''2008-2020'''

In 2008, Granules entered the finished dosage formulations segment, diversifying its business beyond APIs and pharmaceutical formulation intermediates (PFIs). The company received approval from the U.S. [[Food and Drug Administration]] (FDA) for its first [[Abbreviated New Drug Application]] (ANDA) in 2010.<ref>{{Cite news |last=Reporter |first=BS |title=Granules acquires exclusive product rights from US pharma company |url=http://www.business-standard.com/article/companies/granules-acquires-exclusive-product-rights-from-us-pharma-company-116060900277_1.html |archive-url=http://web.archive.org/web/20160816212452/http://www.business-standard.com/article/companies/granules-acquires-exclusive-product-rights-from-us-pharma-company-116060900277_1.html |archive-date=2016-08-16 |access-date=2026-01-29 |language=en-us}}</ref><ref>{{Cite news |last=Kumar |first=N. Ravi |date=2025-11-11 |title=Granules Life Sciences secures first U.S. FDA approval |url=https://www.thehindu.com/business/Industry/granules-life-sciences-secures-first-us-fda-approval/article70266112.ece |access-date=2026-01-29 |work=The Hindu |language=en-IN |issn=0971-751X}}</ref>

In 2013, Granules India acquired Auctus Pharma Laboratories, an API manufacturing facility with regulatory approvals,<ref>{{Cite news |date=2013-11-04 |title=Granules India agrees to acquire Auctus Pharma |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/granules-india-agrees-to-acquire-auctus-pharma/articleshow/25214696.cms?from=mdr |access-date=2026-01-29 |work=The Economic Times |issn=0013-0389}}</ref> and established an API research and development centre at [[Pragathi Nagar]], Hyderabad.<ref>{{Cite web |date=2013-11-04 |title=Granules India to buy Auctus Pharma for Rs 120 crore |url=https://www.thehindubusinessline.com/companies/granules-india-to-buy-auctus-pharma-for-rs-120-crore/article64105047.ece |access-date=2026-01-29 |website=BusinessLine |language=en}}</ref>

In 2014, the company set up Granules Pharmaceuticals Inc., a wholly owned subsidiary in the United States, to focus on formulation research and development and forward integration.<ref>{{Cite web |date=2017-05-25 |title=Granules India to invest ₹220 crore in US subsidiary |url=https://www.thehindubusinessline.com/companies/granules-india-to-invest-220-crore-in-us-subsidiary/article9712718.ece |access-date=2026-01-29 |website=BusinessLine |language=en}}</ref>

In 2015, Granules entered the U.S. over-the-counter (OTC) segment through Granules Consumer Healthcare.<ref>{{Cite web |last=INDIA |first=THE HANS |date=2016-01-22 |title=Granules signs pact with US firm |url=https://www.thehansindia.com/posts/index/Business/2016-01-22/Granules-signs-pact-with-US-firm/201692 |access-date=2026-01-29 |website=www.thehansindia.com |language=en}}</ref>

In 2016, Granules commissioned a manufacturing facility at Visakhapatnam with capabilities for oncology and high-potency APIs, expanding into specialised therapeutic areas.<ref>{{Cite news |last=Market |first=Capital |title=Granules India rises after Vizag facility gets EIR from USFDA |url=https://www.business-standard.com/article/news-cm/granules-india-rises-after-vizag-facility-gets-eir-from-usfda-117100600514_1.html |archive-url=http://web.archive.org/web/20190211001721/https://www.business-standard.com/article/news-cm/granules-india-rises-after-vizag-facility-gets-eir-from-usfda-117100600514_1.html |archive-date=2019-02-11 |access-date=2026-01-29 |language=en}}</ref>

In 2019, the company entered the front-end prescription drug business in the United States under the GPI label, marking its move into direct pharmaceutical sales.<ref>{{Cite web |last=[www.ETPharma.com](www.ETPharma.com) |title=Granules gears for portfolio boost with in-house candidates, eyes Big Ticket rollouts from FY28 |url=https://pharma.economictimes.indiatimes.com/news/pharma-industry/granules-india-targets-major-portfolio-expansion-with-in-house-candidates-and-big-ticket-launches-by-fy28/121927032 |access-date=2026-01-29 |website=ETPharma.com |language=en}}</ref>

'''2021 - 2025'''

In 2021, Granules laid the foundation for a large-scale Multi-Unit Pellet System (MUPS) manufacturing facility, aimed at supporting advanced drug delivery technologies.<ref>{{Cite news |last=The Hindu |first=Special |date=2021-02-08 |title=Granules India to invest ₹800 cr. in expansion |url=https://www.thehindu.com/business/Industry/granules-india-to-invest-800-cr-in-expansion/article33785968.ece |access-date=2026-01-29 |work=The Hindu |language=en-IN |issn=0971-751X}}</ref>

In 2023, Granules entered into a strategic partnership with Greenko ZeroC to enable [[Climate change mitigation|decarbonisation]], advancing its sustainability initiatives.<ref>{{Cite web |last=Livemint |date=2023-01-03 |title=Granules ties up with Greenko ZeroC for green molecule solutions |url=https://www.livemint.com/companies/news/granules-ties-up-with-greenko-zeroc-for-green-molecule-solutions-11672722220644.html |access-date=2026-01-29 |website=mint |language=en}}</ref>

In 2024, Granules Life Sciences (GLS) commenced operations with a planned finished dosage capacity of ten billion units annually, and the Granules CZRO pilot plant also became operational.<ref>{{Cite news |date=2025-11-11 |title=Granules Life Sciences new plant in Hyd gets USFDA nod |url=https://timesofindia.indiatimes.com/business/india-business/granules-life-sciences-new-plant-in-hyd-gets-usfda-nod/articleshow/125252882.cms |access-date=2026-01-29 |work=The Times of India |issn=0971-8257}}</ref>

In 2025, Granules acquired Senn Chemicals AG, a [[Switzerland]]-based contract development and manufacturing organisation (CDMO) specialising in peptide development and manufacturing, through its wholly owned subsidiary Ascelis Peptides Private Limited.<ref>{{Cite news |date=2025-02-21 |title=Granules acquires Swiss firm for Rs 192 cr; forays into CDMO space |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/granules-acquires-swiss-firm-for-rs-192-cr-forays-into-cdmo-space/articleshow/118458838.cms? |access-date=2026-01-29 |work=The Economic Times |issn=0013-0389}}</ref>
==Infrastructure==
[[File:Granules Pharmaceuticals Inc. in Chantilly.jpg|thumb|Granules Pharmaceuticals, Inc. in [[Chantilly, Virginia|Chantilly]], [[Virginia]], US]] Granules has 10 manufacturing facilities out of which seven are in India, two in the US and one in Switzerland.<ref>{{Cite news |last=Mergu |first=Snehal |date=2025-08-22 |title=Can Granules India leverage its strong product pipeline to offset recent profit declines? |url=https://economictimes.indiatimes.com/markets/stocks/news/can-granules-india-leverage-its-strong-product-pipeline-to-offset-recent-profit-declines/articleshow/123442490.cms? |access-date=2026-02-20 |work=The Economic Times |issn=0013-0389}}</ref> The Company has eight research centers, one in Pune, five in Hyderabad, one in Switzerland and one in the US.<ref>{{Cite news |date=2025-12-02 |title=Granules India sets up 2 advanced R&D CoEs at IITH |url=https://timesofindia.indiatimes.com/city/hyderabad/granules-india-sets-up-2-advanced-rd-coes-at-iith/articleshow/125702838.cms |access-date=2026-02-20 |work=The Times of India |issn=0971-8257}}</ref>[[File:Granules India, Breast Health Express mobile cancer screening unit.jpg|thumb|Breast Health Express mobile cancer screening unit by Granules]]

==See also==
*[[Pharmaceutical industry in India]]

==References==
{{Reflist}}

[[Category:Pharmaceutical companies of India]]
[[Category:Manufacturing companies based in Hyderabad, India]]
[[Category:Pharmaceutical companies established in 1984]]
[[Category:Indian companies established in 1984]]
[[Category:1984 establishments in Andhra Pradesh]]
[[Category:Companies listed on the National Stock Exchange of India]]
[[Category:Companies listed on the Bombay Stock Exchange]]
[[Category:Generic drug manufacturers]]

Granules India - Revision history

EthanMarko2: added first info v1 - done